Miyauchi K, Nakai T, Saito S, Yamamoto T, Sato K, Kato K, Nezu M. Miyazaki M, Ito S, Yamamoto M, Suzuki N*.

Renal interstitial fibroblasts coproduce erythropoietin and renin under anaemic conditions. EBioMedicine 2021 Feb 1;64:103209. doi: 10.1016/j.ebiom.2021.103209

プレスリリース

 

Yamazaki S, Hirano I, Kato K, Yamamoto M, Suzuki N*.

Defining the functionally sufficient regulatory region and liver-specific roles of the erythropoietin gene by transgene complementation.

Life Sci 2021 Jan 16;269:119075. doi: 10.1016/j.lfs.2021.119075

 

Kittikulsuth W*, Nakano D, Kitada K, Suzuki N, Yamamoto M, Nishiyama A.

Renal NG2-expressing cells have macrophage-like phenotype and facilitate renal recovery after ischemic injury.

Am J Physiol Renal Physiol 2021 Aug 1;321(2):F170-F178. doi: 10.1152/ajprenal.00011.2021.

プレスリリース

 

Zhang A, Suzuki T, Adachi S, Naganuma E, Suzuki N, Hosoya T, Itoh K, Sporn MB, Yamamoto M*.

Distinct regulations of HO-1 gene expression for stress response and substrate induction.

Mol Cell Biol 2021 Oct 26;41(11):e0023621 (Aug 16:MCB0023621) doi: 10.1128/MCB.00236-21.

 

Nakai T, Iwamura Y, Suzuki N*.

Efficient isolation of interstitial fibroblasts directly from mouse kidneys or indirectly after ex vivo expansion.

STAR Protoc 2021 Dec 17;2:100826. doi: 10.1016/j.xpro.2021.100826

 

Nishikawa K*, Seno S, Yoshihara T, Narazaki A, Sugiura Y, Shimizu R, Kikuta J, Sakaguchi R, Suzuki N, Takeda N, Semba H, Yamamoto M, Okuzaki D, Motooka D, Kobayashi Y, Suematsu M, Koseki H, Matsuda H, Yamamoto M, Tobita S, Mori Y, Ishii M.

Osteoclasts adapt to physioxia perturbation through DNA demethylation.

EMBO Rep 2021 Oct 18:e53035. doi: 10.15252/embr.202153035.

 

Suzuki N*, Iwamura Y, Nakai T, Kato K, Otsuki A, Uruno A, Saigusa D, Taguchi K, Suzuki M, Shimizu R, Yumoto A, Okada R, Shirakawa M, Shiba D, Takahashi S, Suzuki T, Yamamoto M.

Gene expression changes related to bone mineralization, blood pressure and lipid metabolism in mouse kidneys after space travel.

Kidney Int 2021 Nov 9: S0085-2538(21)01030-9. doi: 10.1016/j.kint.2021.09.031.

プレスリリース

 

Uruno A, Saigusa D, Suzuki T, Yumoto A, Nakamura T, Matsukawa N, Yamazaki T, Saito R, Taguchi K, Suzuki M, Suzuki N, Otsuki A, Katsuoka F, Hishinuma E, Okada R, Koshiba S, Tomioka Y, Shimizu R, Shirakawa M, Kensler TW, Shiba D, Yamamoto M*.

Nrf2 plays a critical role in the metabolic response during and after spaceflight.

Commun Biol 2021 Dec 9;4(1):1381. doi: 10.1038/s42003-021-02904-6. PMID: 34887485.

プレスリリース

 

Nezu M, Suzuki N*.

Nrf2 activation for kidney disease treatment – a mixed blessing?

Kidney Int 2021 Jan;99(1):20-22. doi: 10.1016/j.kint.2020.08.033. PMID: 33390228.

(A commentary for "Genetic or pharmacologic Nrf2 activation increases proteinuria in chronic kidney disease in mice" doi: 10.1016/j.kint.2020.07.036")

 

宮崎真理子*, 宮内健一郎, 佐藤浩司, 鈴木教郎.

腎性貧血の発症機序.

臨牀透析 37(1) 13-18 (2021)

 

岩村悠真, 鈴木教郎*.

エリスロポエチンの低酸素誘導的産生制御機構とその破綻による腎性貧血発症の分子機序.

透析療法ネクストXXXVII pp22–30, 2021年10月31日 発行

 

中井 琢, 鈴木教郎*.

遺伝子改変マウスを駆使した腎性貧血の分子病態解析.

in 特集「新しい手法を駆使した腎臓病研究の最前線」

腎と透析 91(5) 890–895 (2021)

 

The 12th Japan Society of Hematology International Symposium

JSH-ASH Joint Session "Development of molecular targeting therapy for bone marrow failure and anemia"

Presentation title: Molecular mechanism of erythropoietin deficiency in kidney disease  (Norio Suzuki)

May 14-15, 2021 (Kamakura & online)